Top Authors

• Most frequent coverage on OSIR

• 
  Mike Havrilla (1926 followers)

  • Stem Cell Index Surges in Past Week (Mon, May 11)
  • FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson (Thu, Apr 23)
  • Banking on NeoStem (Sun, Apr 12)

  More by Mike Havrilla on OSIR »
• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)
  • 'Lucky 13 Portfolio': Fuel Systems and Three Cancer Drug Makers (Tue, Aug 25)

  More by Justin M. Hall on OSIR »
• 
  TickerSense (134 followers)

  • Russell 3000's Best and Worst Stocks, Week and Year to Date (Sat, Mar 24)
  • Russell 3000's Best and Worst Stocks, Week and Year to Date (Sun, Mar 11)
  • Russell 3000's Best Performing Stocks of 2006 (Tue, Dec 26)

  More by TickerSense on OSIR »

• Most followed authors on OSIR

• 
  Mike Havrilla (1926 followers)

  • Stem Cell Index Surges in Past Week (Mon, May 11)
  • FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson (Thu, Apr 23)
  • Banking on NeoStem (Sun, Apr 12)

  More by Mike Havrilla on OSIR »
• 
  Richard Shaw (1068 followers)

  • Little Rays of Sunshine in the Markets (Fri, Feb 6)

  More by Richard Shaw on OSIR »
• 
  Zacks.com (1057 followers)

  • Optimistic on Osiris Therapeutics (Fri, May 8)
  • Osiris Hits a Speedbump in Crohn's Program (Fri, Mar 27)
  • Know Your Options When Investing in Biotech Stocks (Mon, Mar 2)

  More by Zacks.com on OSIR »

• Newest authors on OSIR

• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)
  • 'Lucky 13 Portfolio': Fuel Systems and Three Cancer Drug Makers (Tue, Aug 25)

  More by Justin M. Hall on OSIR »
• 
  M. E. Garza (520 followers)

  • Cryo-Cell: The Stem Cell Sector's Profit Leader, Part 2 (Thu, Aug 27)
  • Cryo-Cell: The Stem Cell Sector's Profit Leader, Part 1 (Thu, Aug 27)
  • Adult Stem Cell Drugs and Therapies Are the Next Big Market (Thu, Jun 18)

  More by M. E. Garza on OSIR »
• 
  optionMONSTER (657 followers)

  • Expiration Trade Behind Osiris Activity (Fri, Nov 20)

  More by optionMONSTER on OSIR »

• Most commented on OSIR

• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)
  • 'Lucky 13 Portfolio': Fuel Systems and Three Cancer Drug Makers (Tue, Aug 25)

  More by Justin M. Hall on OSIR »
• 
  Mike Havrilla (1926 followers)

  • Stem Cell Index Surges in Past Week (Mon, May 11)
  • FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson (Thu, Apr 23)
  • Banking on NeoStem (Sun, Apr 12)

  More by Mike Havrilla on OSIR »
• 
  Ketan Desai (18 followers)

  • 10 Biotechs in Stem Cells that Could Profit Under the Democrats (Sun, Jun 1)

  More by Ketan Desai on OSIR »